Liu et al. [37] observed similar results with BTK inhibitors and Btk-deficient mice, and importantly observed decreased NLRP3 inflammasome activation in primary myeloid cells from patients with X-linked agammaglobulinemia (XLA) that have mutations in BTK. Here, BTK is linked to Bruton-type agammaglobulinemia.